12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
05:01 , Feb 15, 2019 |  BC Extra  |  Financial News

Stealth Bio prices $78M IPO at bottom end of range

Stealth BioTherapeutics Corp. (NASDAQ:MITO) closed down $0.10 to $11.90 Friday after raising $78 million in its IPO. Late Thursday, the company priced more ADSs than anticipated at the bottom end of its proposed range. The...
05:21 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late on Dec. 28, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on...
19:24 , Dec 30, 2018 |  BC Extra  |  Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

Stealth BioTherapeutics Corp. (Newton, Mass.) proposed an IPO on NASDAQ late Friday, less than six months after filing to list on the Hong Kong stock exchange. The prospectus filed with the SEC on Friday does...
00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
19:59 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Stealth, AOBiome propose Hong Kong offerings

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on July 3 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that...
22:10 , Jul 3, 2018 |  BC Extra  |  Financial News

Stealth, AOBiome propose Hong Kong offerings

Stealth BioTherapeutics Corp. (Newton, Mass.) and AOBiome Therapeutics Inc. (Cambridge, Mass.) each proposed on Tuesday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX). Stealth’s lead candidate is elamipretide, a mitochondrial-targeting tetrapeptide that binds...
18:35 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million June 18 through two convertible note rounds led by Nan Fung Technology's Pivotal Beta and Morningside Ventures, respectively. Also participating were funds associated with Atlantis Investment Management,...
22:08 , Jun 18, 2018 |  BC Extra  |  Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

Stealth BioTherapeutics Inc. (Newton, Mass.) raised $100 million Monday through two convertible note rounds led by Nan Fung Technology's Pivotal Beta. Also participating were funds associated with Atlantis Investment Management, BVCF Management, CMBC Capital Holdings,...
17:01 , Aug 10, 2017 |  BC Week In Review  |  Clinical News

Stealth begins Phase II/III of elamipretide in Barth syndrome

Stealth BioTherapeutics Inc. (Newton, Mass.) began the double-blind, crossover, U.S. Phase II/III TAZPOWER trial to evaluate subcutaneous elamipretide (MTP-131) in ≥12 patients ages ≥12 with genetically confirmed Barth syndrome. Patients will receive 40 mg elamipretide...